ReviewFrontiers in immunology2018
Clinical Grade Regulatory CD4
Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 70 citations in OpenAlex.
- Nonclinical safety assessment of SBT777101, a CAR-engineered regulatory T cell therapy for autoimmune diseases.Toxicological sciences : an official journal of the Society of Toxicology · 2026Article
- Immunosenescence and inflammaging in Parkinson's disease: mechanisms and therapeutic prospects.Frontiers in immunology · 2026Review
- Associations Between Gastroenteropancreatic Neuroendocrine Neoplasms and Inflammatory Factors: Insights From a Two-Sample Mendelian Randomization Analysis.Canadian journal of gastroenterology & hepatology · 2025Article
- Navigating the manufacturing, testing and regulatory complexities of regulatory T cells for adoptive cell therapy.Frontiers in immunology · 2025Review
- Past, present, and future of cell replacement therapy for parkinson's disease: a novel emphasis on host immune responses.Cell research · 2024Review
- Developing targeted therapies for neuroblastoma by dissecting the effects of metabolic reprogramming on tumor microenvironments and progression.Theranostics · 2024Article
- Chimeric antigen receptor T cell therapy for the treatment of systemic rheumatic diseases: a comprehensive review of recent literature.Annals of medicine and surgery (2012) · 2023Article
- Co-transplantation of autologous TNature · 2023Article
- Intrauterine desensitization enables long term survival of human oligodendrocyte progenitor cells without immunosuppression.iScience · 2023Article
- Preclinical assessment of antigen-specific chimeric antigen receptor regulatory T cells for use in solid organ transplantation.Gene therapy · 2023Article
- Monitoring regulatory T cells as a prognostic marker in lung transplantation.Frontiers in immunology · 2023Review
- Barriers to Treg therapy in Europe: From production to regulation.Frontiers in medicine · 2023Review
- Interferon-γ enhances the immunosuppressive ability of canine bone marrow-derived mesenchymal stem cells by activating the TLR3-dependent IDO/kynurenine pathway.Molecular biology reports · 2022Article
- Study Design: Human Leukocyte Antigen Class I Molecule AKidney international reports · 2022Article
- Different subpopulations of regulatory T cells in human autoimmune disease, transplantation, and tumor immunity.MedComm · 2022Review
- Established and Emerging Treatments of Skin GvHD.Frontiers in immunology · 2022Review
- mTORC1 Inhibition Protects Human Regulatory T Cells From Granzyme-B-Induced Apoptosis.Frontiers in immunology · 2022Article
- CD4Frontiers in immunology · 2022Review
- A Novel GMP Protocol to Produce High-Quality Treg Cells From the Pediatric Thymic Tissue to Be Employed as Cellular Therapy.Frontiers in immunology · 2022Article
- Everolimus-Induced Immune Effects after Heart Transplantation: A Possible Tool for Clinicians to Monitor Patients at Risk for Transplant Rejection.Life (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regulatory T cells (Tregs) are CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.